Medtech IPO & SPAC Outlook for 2026: Medline, MiniMed, and the Return of Public Markets
A comprehensive analysis of the medtech and healthcare IPO landscape in 2026 — from Medline's record $6.3B listing and Medtronic's MiniMed Diabetes spinoff IPO to digital health debuts, SPAC resurgence, and what's in the pipeline.
The Medtech IPO Window Is Open
After a three-year lull that followed the 2021 IPO boom, the medtech and healthcare public offering market came roaring back at the end of 2025 — and 2026 is shaping up to be the strongest year for medtech capital markets in half a decade.
The catalyst was clear: Medline Industries' $6.26 billion IPO in December 2025, the largest IPO globally that year and the largest US stock debut in four years, proved that public markets have a massive appetite for high-quality medtech assets. Shares surged 41% on the first day of trading, opening at $35 against a $29 IPO price and climbing to approximately $41 by close (FT; LinkedIn/PE Insights; Axios).
Since then, the pipeline has accelerated. Medtronic's MiniMed Diabetes spinoff launched its IPO roadshow in February 2026, seeking $742 million. Multiple digital health companies have gone public. And SPACs — once dismissed as dead — are staging a disciplined comeback.
"I think 2026 has the potential to be a strong year in the public capital markets for medtech and medical devices, both in terms of appreciation of value for large and mid-cap, as well as for small-cap," said an analyst quoted by MD+DI in their 2026 medtech forecast (MD+DI).
The Blockbuster Medtech IPOs
1. Medline Industries: The Record-Breaker ($6.26B)
Medline's IPO was not just the biggest medtech listing in years — it was a defining moment for the PE-backed medtech thesis and for the broader capital markets.
| Detail | Value |
|---|---|
| IPO date | December 2025 |
| Exchange | Nasdaq |
| Shares offered | 216 million |
| IPO price | $29 per share |
| Proceeds raised | $6.26 billion (upsized from initial $5.37B target) |
| Opening price | $35 (+21% from IPO) |
| First-day close | ~$41 (+41% from IPO) |
| Valuation | $50+ billion |
| 2024 net sales | $25.5 billion |
| PE sponsors | Blackstone, Carlyle, Hellman & Friedman (acquired 2021 for ~$34B) |
| PE equity invested | ~$3.5 billion |
Sources: FT; Axios; TradingView; LinkedIn (PE Insights); BioWorld.
Why it mattered: Medline was the fifth US-listed firm to raise more than $5 billion in an IPO in the past decade and demonstrated that private equity can successfully execute a buy-improve-exit strategy in medtech at enormous scale. The original 2021 buyout by Blackstone, Carlyle, and Hellman & Friedman (with GIC as co-investor) valued Medline at roughly $34 billion. After four years of PE ownership — during which Medline executed over $1 billion in acquisitions and significant international expansion — the company went public at a $50B+ valuation (Axios; BioWorld).
Credit impact: Fitch Ratings expected a multi-notch credit upgrade for Medline following approximately $4 billion in post-IPO debt reduction, addressing the leverage from the 2021 leveraged buyout (TradingView).
Significance for 2026 pipeline: Multiple bankers and analysts cited Medline as proof that the IPO window is open for large-scale, PE-backed medtech and healthcare companies. The deal "restored faith in leveraged buyouts at a time when many limited partners in private equity funds are questioning the model's viability" (Axios).
2. Medtronic MiniMed: The Diabetes Spinoff IPO (~$742M)
Medtronic's decision to spin off its Diabetes business as an independent company called MiniMed represents one of the most closely watched medtech IPOs of 2026.
Timeline:
- December 19, 2025 — Medtronic filed a registration statement on Form S-1 with the SEC (Medtronic Press Release)
- February 24, 2026 — MiniMed announced the launch of its IPO roadshow, seeking approximately $742 million in proceeds (Medtronic Press Release; Law360)
- Expected pricing — Q1-Q2 2026
Strategic context: The separation allows MiniMed to operate with the agility of a standalone company in the fast-moving diabetes device market, which is being reshaped by:
- Continuous glucose monitoring (CGM) expansion — Abbott's FreeStyle Libre and Dexcom are growing rapidly, with CGM devices now available over-the-counter to consumers regardless of diabetes status (MD+DI)
- Closed-loop insulin delivery — Integration between CGM sensors and insulin pumps is the major growth frontier
- Competitive pressure — Tandem Diabetes Care, Beta Bionics, Sequel Med Tech, and Ypsomed are all partnering with CGM sensor makers to offer integrated systems (IQVIA MedTech Trends 2026)
The name "MiniMed" is a callback to the pioneering insulin pump company that Medtronic acquired in 2001. As one LinkedIn analysis noted, the MiniMed IPO follows the Medline IPO and signals continued strong investor appetite for medtech listings (Equityswarm via LinkedIn).
Healthcare & Digital Health IPOs: The 2025-2026 Wave
Beyond the mega-cap medtech listings, a significant wave of healthcare and digital health companies went public in 2025 and early 2026.
Major Healthcare IPOs of 2025
| Company | Segment | IPO Proceeds | Exchange | Date |
|---|---|---|---|---|
| Medline Industries | Medical supplies / distribution | $6.26B | Nasdaq | Dec 2025 |
| Caris Life Sciences | Precision medicine / AI TechBio | $494M | — | Jun 2025 |
| Lumexa Imaging Holdings | Outpatient diagnostic imaging | $462.5M | — | 2025 |
| Hinge Health | Digital MSK care | $437.3M | — | 2025 |
| Omada Health | Chronic condition management | $120M | Nasdaq | Jun 2025 |
Sources: Xtalks; Healthcare Dive; BioWorld.
Early 2026 IPO Activity
| Company | Segment | IPO Proceeds | Date |
|---|---|---|---|
| Medtronic MiniMed | Diabetes devices (insulin pumps) | ~$742M (target) | Roadshow Feb 2026 |
| Eikon Therapeutics | Protein-tracking / oncology platform | ~$380M | Feb 2026 |
| Agomab Therapeutics | ALK5-focused fibrosis pipeline | $200M | Feb 2026 |
| SpyGlass Pharma | Intraocular drug delivery (glaucoma) | — | Feb 2026 |
Sources: DeciBio Healthcare Investment Roundup Feb 2026; Medtronic Press Release; Law360.
The Digital Health IPO Thesis
The 2025 digital health IPOs proved that companies can go public successfully even in a challenging market — but the bar has risen dramatically since 2021:
Hinge Health tried to "run its business like a public company for two years before its IPO, doing mock earnings calls and deciding the firm had to beat and raise expectations for four quarters before going public," according to CEO Daniel Perez speaking at HLTH (Healthcare Dive).
Omada Health went public in June 2025 after operating as a private company for 14 years, demonstrating the patience required in the current market (Xtalks).
Baird's healthcare investment banking director Sasha Kelemen noted at HLTH that watching Omada and Hinge "redefined the blueprint of what it could take to be a public company" — emphasizing profitability or clear paths to profitability, not just revenue growth (Healthcare Dive).
The SPAC Resurgence: A Disciplined Second Act
SPACs Are Back — But Different
After the speculative SPAC boom of 2020-2021 (when 613 SPACs raised $162 billion) and the subsequent crash, SPACs have made a surprising comeback. According to EY's US IPO trends report, nearly 150 new SPAC vehicles were formed in 2025 — more than 2023 and 2024 combined. The increase in unredeemed SPAC trusts with ample time to transact "creates additional opportunities for companies seeking public listings" (EY US IPO Trends). This has been dubbed "SPAC 4.0" — a disciplined reinvention of the structure (Foley & Lardner). According to ARC Group research, the resurgence is driven by three factors fundamentally different from the 2020-2021 era:
- Institutional capital — Repeat sponsors with healthcare track records are leading new SPAC formations, replacing the celebrity and retail-driven vehicles of the earlier boom
- Improved regulatory clarity — SEC rules enacted in 2024-2025 have strengthened disclosure requirements, investor protections, and de-SPAC accounting standards
- Maturing ecosystem — Investors now view SPACs as "better governed and more predictable, supported by repeat sponsors who know how to navigate both regulatory and market expectations" (ARC Group)
Healthcare SPAC Activity
ICR's 2026 report projects continued growth in SPAC IPOs, with healthcare and medtech representing a significant share of activity (O'Dwyer's PR News). While specific healthcare SPAC deal data for 2026 is still emerging, several trends are clear:
- Quality over quantity — The number of new SPAC formations is well below the 2021 peak, but the average trust size and sponsor quality are significantly higher
- Medtech and diagnostics targets — SPACs are targeting pre-revenue or early-revenue medtech companies that are too small for traditional IPOs but too large for continued VC funding
- International targets — SPACs are increasingly used by non-US medtech companies seeking US public listings, particularly from Israel, Europe, and Southeast Asia
How SPACs Compare to Traditional IPOs
| Factor | Traditional IPO | SPAC Merger |
|---|---|---|
| Time to public | 12-18 months | 3-6 months |
| Revenue requirement | Generally profitable or near-profitable | Can be pre-revenue |
| Disclosure flexibility | SEC-regulated projections (limited) | Can share forward projections in SPAC proxy |
| Cost | 5-7% underwriting fee | Lower underwriting but higher dilution from warrants/founder shares |
| Market timing risk | High (pricing depends on market conditions at IPO) | Lower (price negotiated with SPAC sponsor) |
| Investor certainty | Bookbuild process | PIPE commitment + trust redemption risk |
For medtech companies, the SPAC route remains attractive when:
- The company is pre-revenue but has FDA clearance/CE marking
- The technology story requires more forward-looking projections than a traditional S-1 allows
- Speed to market matters (e.g., competitive dynamics or funding runway constraints)
The 2026 IPO Pipeline: Companies to Watch
Confirmed or Highly Likely
- Medtronic MiniMed — Diabetes spinoff IPO in progress, ~$742M target
- PE-backed medtech exits — Following Medline's success, multiple PE firms are expected to pursue IPO exits for their largest portfolio companies in 2026
Potential IPO Candidates (Based on Market Analysis)
Industry analysts have identified several specific companies and categories likely to test the IPO window in 2026:
1. Zelis Healthcare — A healthcare payments infrastructure company widely anticipated as a 2026 mega-listing candidate alongside MiniMed (Healthcare.digital)
2. CMR Surgical — The UK-based surgical robotics company has raised over $1 billion total (including $200M in late 2025) and is considered a potential NASDAQ or LSE IPO candidate (Healthcare.digital UK MedTech Report)
3. AI-native healthcare platforms — Companies like Abridge (clinical documentation AI) and Commure (healthcare operating system) are positioning for potential IPOs, promising "fundamental labor substitution" in clinical workflows (Healthcare.digital)
4. Late-stage digital health companies with proven revenue models and profitability paths, following the Hinge Health and Omada playbook. AI-enabled digital health companies captured 54% of total funding in 2025 (up from 37%), commanding a ~19% premium on deal size (Rock Health)
5. Medtech CDMO platforms — PE-assembled contract manufacturing platforms that have reached scale through buy-and-build may pursue IPO exits. Alvarez & Marsal has identified CDMO platforms as the major catalyst for medtech M&A in 2026 (MD+DI)
6. Medtronic's remaining portfolio — If the MiniMed IPO succeeds, it could encourage Medtronic to consider further spinoffs
Factors Shaping the 2026 IPO Market
Tailwinds
- Medline proof-of-concept — The record-breaking IPO demonstrated that public markets have massive appetite for medtech assets
- PE exit pressure — With PE holding periods lengthening and LP demands for distributions increasing, PE firms are eager to use the IPO window
- Medtech sector strength — Large-cap medtech stocks (Boston Scientific, Intuitive Surgical) have performed well, creating a favorable comparable valuation environment
- Global IPO momentum — According to EY, 2025 saw 1,293 IPOs completed worldwide, raising $171.8 billion — with proceeds jumping 39% year-over-year despite steady deal counts, highlighting growing investor confidence (EY US IPO Trends)
- Innovation cycle — AI integration, surgical robotics, and connected devices are driving investor excitement about the sector's growth prospects
- Interest rate trajectory — If rates stabilize or decline, growth-stage medtech valuations should improve
Headwinds
- Tariff uncertainty — Trade policy volatility has hit medtech stocks and could delay IPO timing for companies with significant manufacturing exposure to tariffed regions
- Geopolitical risk — Ongoing uncertainty around China-US trade relations affects medtech companies with Asian supply chains
- Market volatility — Periods of elevated VIX (Volatility Index) can shut the IPO window temporarily
- Regulatory uncertainty — Changes to FDA policy, CMS reimbursement, and FTC merger enforcement create unpredictability
- Post-IPO performance pressure — After the 2021 SPAC wave saw many companies trade well below their de-SPAC prices, investors are demanding higher-quality assets and more reasonable valuations
Lessons from the 2025-2026 IPO Wave
For Companies Considering an IPO
- Profitability matters — The days of "growth at all costs" IPOs are over. Hinge Health and Omada both emphasized profitability paths before going public. Medline was already profitable with $25.5B in revenue.
- Run like a public company first — Hinge Health's approach of doing mock earnings calls and beating internal targets for four quarters before filing is becoming best practice.
- Size matters — Medline's $6.26B raise and 41% first-day pop show that larger, more established companies get better market reception. The median healthcare IPO in 2025 was smaller but still required proof of a viable business model.
- PE backing can help — Having institutional sponsors with track records provides credibility and ensures a disciplined operational focus during the lead-up to listing.
For Medtech Investors
- Watch the MiniMed pricing — The Medtronic Diabetes IPO will signal whether the market differentiates between a supply chain giant (Medline) and a competitive device company in a rapidly evolving segment
- PE exit wave is coming — Multiple PE-backed medtech companies are likely to test the IPO window in 2026, creating a pipeline of new public medtech investments
- Digital health remains selective — Not every digital health company will get the Hinge/Omada treatment. Investors are screening for recurring revenue, clinical evidence, and paths to profitability
- SPAC due diligence is critical — The new SPAC wave comes with improved structures, but investors still need to scrutinize sponsor terms, warrant dilution, and trust redemption dynamics
IPO vs. M&A Exit: The 2026 Decision Framework
For medtech companies and their investors, the choice between IPO and trade sale has become more nuanced:
| Factor | Favors IPO | Favors M&A Exit |
|---|---|---|
| Company size | Revenue >$500M or strong growth trajectory | Any size |
| Market conditions | Strong equity markets, open window | Always available for right asset |
| Valuation | Public market premiums (20-40x+ EBITDA for growth) | Strategic premium (typically 15-25x EBITDA) |
| Speed | 12-18 months preparation | 6-12 months |
| Ongoing obligations | Quarterly reporting, SOX compliance, public scrutiny | None (acquisition) |
| Founder control | Retained (with dual-class possible) | Lost in most acquisitions |
| Future capital access | Easy (secondary offerings) | Dependent on acquirer |
The 2025-2026 environment uniquely favors IPOs for large medtech assets because:
- Public market multiples for high-growth medtech exceed strategic M&A premiums
- PE firms prefer IPO exits when public valuations are high (as they can sell down gradually)
- The Medline success created a "greenlight" signal for investment banks and underwriters
Key Takeaways
- Medline's $6.26B IPO reopened the medtech IPO window after a three-year lull, with shares surging 41% on the first day — the largest US IPO of 2025
- Medtronic's MiniMed Diabetes spinoff IPO (seeking ~$742M) is the most closely watched medtech listing of 2026
- Digital health IPOs have matured — Hinge Health and Omada proved that profitability and operational maturity are now prerequisites
- SPACs are back with better governance, institutional sponsors, and regulatory clarity — but selectivity is key
- The 2026 pipeline is strong, with PE-backed exits, AI-enabled medtech companies, and surgical robotics firms all potentially testing the public markets
Sources: FT; Axios; TradingView; LinkedIn (PE Insights, Equityswarm); BioWorld; MassDevice; Medtronic Press Release; Law360; MD+DI; Healthcare Dive; Xtalks; DeciBio; ARC Group; O'Dwyer's PR News; IQVIA MedTech Trends 2026; Bain & Company Global Healthcare PE Report 2026.